Speakers:

• Sivajanan Sivapalan
• Michael Boivin

Learning Objectives

• Module 1
• To describe current global recommendations to help minimize over-use of short-acting beta-agonists as monotherapy and optimize controller therapy.
• Module 2
• Assess the level of control of an asthma patient
• Identify opportunities in the pharmacy to optimize asthma control for their patients
• List common drug therapy problems in patients with asthma that may lead to increased risk of exacerbations
• Apply strategies to effectively assess, intervene and partner with patients and their healthcare providers to improve asthma care

Invitation available to download here.

Webinar link will be provided after RSVPing

Speaker – Dr. Peter Lin M.D
Moderator- Sivajanan Sivapalan MPharm. R.Ph. CDE

Learning Objectives

• To discuss the evolution of modern diabetes treatment: treating beyond A1c.
• To highlight recent clinical trial evidence for cardiovascular and renal outcomes with SGLT2 inhibitors.
• Discuss the differences and significance of CVD primary and secondary prevention.
• Apply the evidence of SGLT2 inhibitors in the management of vascular risk, renal risk and heart failure.

Invitation available to download here.

Webinar Link will be provided after RSVPing

Presenter: Carolyn Whiskin RPh, BScPhm, NCMP
 

Learning Objectives

• Describe the process by which biosimilars are approved and regulated by Health Canada
• Explain key data on biosimilars used in rheumatology
• Apply experiences and practical tips provided by experts to improve communication with patients on the use of biosimilars
• Use the acquired knowledge to educate patients and address their questions on the use of biosimilars with confidence

Invitation available to download here.

Microsoft Teams link will be provided after RSVPing

Title: Current Clinical Approaches to Fracture Management

Speakers: Dr Rick Adachi and Carolyn Whiskin R.Ph.

Date: Novemeber 26th 2020

Time: 7p.m. to 8p.m.

Upon completion of this presentation, pharmacists will be able to:

• ·        Implement effective treatment and management plans for all osteoporosis patients at risk for fracture
• ·        Discuss the consequences of fracture and importance of therapy with patients to ensure awareness of their disease, treatment and management

Download invitation

Title: The Power of Brief Interventions for Pharmacists as Partners in Asthma Care

Speakers: Michael Boivin & Sivajanan Sivapalan

Date: Novemeber 11th 2020

Time: 7p.m. to 8p.m.

Upon completion of this presentation, pharmacists will be able to:

• Assess the level of control of an asthma patient

• Identify opportunities in the pharmacy to optimize asthma control

for their patients

• List common drug therapy problems in patients with asthma that

may lead to increased risk of exacerbations

• Apply strategies to effectively assess, intervene and partner with

patients and their healthcare providers to improve asthma care

Download invitation

Speaker: Diane McIntosh MD, FRCPC, Psychiatry Clinical Assistant Professor,University of British Columbia, Vancouver, BC

Moderator: Siva Sivapalan MPharm. R.Ph. CDE Community Pharmacist

Program objectives
• Review the etiology and evidence of ADHD throughout the lifespan
• Discuss the importance of assessment, diagnosis and treatment
• Examine the treatments available to control the symptoms of ADHD
• Highlight the processes available to access treatment medications
• Identify methods to manage side effects and medication interactions

Agenda
7.00 PM Introduction
7.10 PM Is ADHD Fake News?
8.00 PM Q&A
8.15 PM Close

Download invitation

Presented By:
Ron Vender, MD, FRCPC Dermatologist, Hamilton ON

Moderated by:
Fabio De Rango BScPhm. R.Ph., Pharmacist, Shoppers Drug Mart Oakville

Learning Objectives:

• Typical presentations of psoriasis and its impact on patients’ quality of life
• Halobetasol 0.01%/tazarotene 0.045% as a new therapeutic option for the management of patients with moderate to severe plaque psoriasis
• The role of the polymeric emulsion vehicle technology for halobetasol 0.01%/tazarotene 0.045%

Date: Tuesday Oct 6th, 2020

Time: Presentation at 6:30pm – 7:30pm

Location: Virtually via Microsoft Teams